HC Wainwright Brokers Lower Earnings Estimates for Evotec

Key Points

• HC Wainwright cut Evotec’s Q3 2026 EPS estimate to a loss of $0.14 from a projected loss of $0.04, while maintaining its “Buy” rating and $4.00 price target.
• Analyst sentiment is mixed: TD Cowen and Berenberg downgraded the stock to “Hold,” while Wall Street Zen and Weiss Ratings maintain bearish views. MarketBeat reports a consensus “Hold” rating and $3.00 price target.
• Evotec shares opened at $1.96, near their 12-month low of $1.90, and institutional investors own approximately 5.81% of the company.

Evotec AG (NASDAQ:EVO - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share estimates for Evotec in a note issued to investors on Friday, August 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.14) per share for the quarter, down from their previous forecast of ($0.04). HC Wainwright currently has a "Buy" rating and a $4.00 target price on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Evotec's Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.83) EPS, FY2029 earnings at $0.21 EPS and FY2030 earnings at $0.28 EPS.

Other research analysts have also issued research reports about the company. TD Cowen lowered Evotec from a "buy" rating to a "hold" rating and set a $2.00 price target on the stock. in a research note on Wednesday, July 15th. Wall Street Zen cut Evotec from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Evotec in a research note on Tuesday, July 21st. Finally, Berenberg Bank lowered shares of Evotec from a "buy" rating to a "hold" rating in a report on Thursday, July 16th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.00.

Evotec Price Performance

Shares of NASDAQ EVO opened at $1.96 on Tuesday. Evotec has a 12 month low of $1.90 and a 12 month high of $4.27. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62. The company has a 50-day simple moving average of $2.36 and a 200-day simple moving average of $2.79.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Evotec in the second quarter worth about $66,000. Marshall Wace LLP acquired a new position in shares of Evotec in the second quarter worth about $169,000. BNP Paribas Financial Markets boosted its holdings in Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock valued at $50,000 after purchasing an additional 4,600 shares during the last quarter. Finally, Snowden Capital Advisors LLC acquired a new stake in Evotec during the 2nd quarter valued at approximately $122,000. 5.81% of the stock is owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source